Genkyotex : Résultats FY 2018 sans surprise – Résultats finaux phase 2 au T2 (CBP)
>Résultats FY 2018 sans surprise - La biotech française publie ce matin ses résultats annuels. Le niveau de trésorerie ressort à 10.3 M€ fin 2018 (déjà connue).Le groupe profite de cette publication pour faire un point d’étape sur le déroulement clinique de GKT831 dans la Cholangite Biliaire Primitive (CBP). L’étude se déroule « conformément au plan ». Les résultats finaux sont attendus au printemps de cette année (90% des patients ont terminés les 24 semaines de...Genkyotex is engaged in the identification and development of selective NADPH Oxidase ("NOX") inhibitors to treat specific diseases, the therapeutic benefit of which has not yet been demonstrated. Co. is developing a new therapeutic approach based on the selective inhibition of NOX enzymes which are identified as potentially key factors in the development of certain complex illnesses that are difficult to treat, such as hepatic, pulmonary and renal fibrosis, certain forms of cancer, neurodegenerative diseases or even hearing problems. The capacity of NOXs to simultaneously regulate protein networks makes them a therapeutic target.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.